TransMedics Group, Inc.

What they do

TransMedics developed the Organ Care System (OCS), a portable warm perfusion platform that keeps donor organs functioning outside the body rather than on ice. Three products, OCS Heart, OCS Lung and OCS Liver, hold FDA Pre-Market Approval for both donation after brain death (DBD) and donation after circulatory death (DCD) organs. The company also operates the National OCS Program (NOP), a turnkey service providing organ procurement, OCS perfusion management, and aviation and ground transplant logistics across the United States. Revenue comes from OCS device and consumable sales plus NOP service fees.

Revenue drivers

• Product revenue (OCS Heart, Lung, Liver) — Sales of the OCS consoles and disposables used to perfuse and monitor donor organs. Product revenue was $111.2 million in Q2 2026, up 16% year over year, roughly 59% of total quarterly revenue.
• Service revenue (NOP) — Fees for outsourced organ procurement, OCS perfusion management, and dedicated aviation and ground transport logistics. Service revenue was $78.8 million in Q2 2026, up 29% year over year, roughly 41% of total quarterly revenue and the faster-growing line.
• United States transplant centers — The NOP is described as serving transplant programs in the United States; the company states it intends to grow commercial sales in the U.S. and select non-U.S. markets.
• OCS units sold for clinical trials — The company states it has historically funded operations partly through revenue from sales of OCS products for use in clinical trials, alongside commercial product and NOP service revenue.

Recent performance

Second quarter 2026 total revenue was $189.9 million, up 21% from $157.4 million in Q2 2025, with product revenue of $111.2 million (+16%) and service revenue of $78.8 million (+29%). Net income was $14.7 million, or $0.41 per diluted share, versus $0.92 in the prior-year quarter; adjusted net income was $16.2 million, or $0.44 per share. Income from operations fell 35% to $23.7 million and operating margin declined to 12.5% from 23.2%, a 1,074 basis point drop. For the six months ended June 30, 2026, revenue was $363.9 million and net income $22.0 million. Full-year 2025 revenue was $605.5 million with net income of $190.3 million and operating cash flow of $192.8 million.

Strategy

Management describes itself as building a growth company and is deploying capital behind four stated growth opportunities, with the CEO citing record revenue, accelerating service growth and sequential gross margin expansion alongside aggressive investment. On July 1, 2026 the company completed a strategic investment in PAD Aviation, a Germany-based private aviation operator, as a first step toward a dedicated organ transplantation air logistics network across Europe and beyond. Full-year 2026 revenue guidance excluding PAD Aviation was narrowed upward at the low end to $737 million to $757 million. The company also flags it will opportunistically evaluate acquisitions of additional aircraft for aviation transportation services, with uncertain timing and amounts.

Risks

• Quarterly results are hard to predict — The company states results fluctuate quarter to quarter based on availability of donor organs and transplant center surgeons, which is unpredictable and affects OCS procedure volume and NOP demand.
• Indebtedness under the CIBC credit agreement — As of December 31, 2025, the outstanding principal balance of long-term debt under the CIBC Credit Agreement was $60.0 million.
• Dependence on continued commercial sales — Management states ability to generate revenue sufficient for sustained profitability depends on continued commercial sales of products and services, and that it may need equity or debt financings if it cannot.
• OPTN contracting structure in flux — UNOS operated the Organ Procurement and Transplantation Network under a sole-vendor federal contract until 2024, and HRSA has moved toward a multi-vendor model, a change the company describes in its risk discussion.

Outlook

Management raised the low end of full-year 2026 revenue guidance excluding PAD Aviation to a range of $737 million to $757 million. It expects operating and capital expenditures to continue increasing as it grows commercial sales in the United States and select non-U.S. markets. The company frames the PAD Aviation investment as the first step toward a dedicated European organ transplantation air logistics network. It cautions it cannot accurately predict the timing or amount of increased expenses or whether it will maintain profitability.